المؤلفون: Claessens, AKM, Ibragimova, KIE, Geurts, SME, Bos, Monique, Erdkamp, FLG, Tjan-Heijnen, VC

المصدر: Claessens , AKM , Ibragimova , KIE , Geurts , SME , Bos , M , Erdkamp , FLG & Tjan-Heijnen , VC 2020 , ' The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice ' , Critical Reviews in Oncology/Hematology , vol. 153 , 102988 .

مصطلحات الفهرس: dk/atira/pure/keywords/researchprograms/AFL001000/EMCOR01; name=EMC OR-01, dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being, article

URL: https://pure.eur.nl/en/publications/aca237c0-0697-4919-b6ee-dc62b6a1b3ed

المؤلفون: Geurts SME; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. sandra.geurts@mumc.nl., Ibragimova KIE; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Ding N; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Maaskant SAJG; Department of Surgery, Máxima Medical Center, Eindhoven, The Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., van Nijnatten TJA; Department of Radiology and Nuclear Medicine, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (2), pp. 287-302. Date of Electronic Publication: 2024 Feb 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/mortality , Breast Neoplasms*/pathology , Breast Neoplasms*/therapy , Receptor, ErbB-2*/metabolism , Registries*, Humans ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Neoplasm Metastasis ; Kaplan-Meier Estimate ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use

المؤلفون: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Laczkó D; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., de Fallois A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., van Kats MACE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

المصدر: Clinical breast cancer [Clin Breast Cancer] 2024 Feb; Vol. 24 (2), pp. 103-111. Date of Electronic Publication: 2023 Nov 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Humans ; Female ; Trastuzumab ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Receptor, ErbB-2/metabolism ; Progression-Free Survival ; Proportional Hazards Models

المؤلفون: Ibragimova KIE; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Meegdes M; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Vriens IJH; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (2), pp. 239-251. Date of Electronic Publication: 2023 Jan 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism, Humans ; Female ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

المؤلفون: Meegdes M; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Lobbezoo DJA; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Vriens IJH; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Kooreman LFS; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., Hochstenbach-Waelen A; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Smidt ML; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Geurts SME; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Apr; Vol. 192 (2), pp. 331-342. Date of Electronic Publication: 2022 Jan 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/epidemiology , Breast Neoplasms*/metabolism , Breast Neoplasms*/therapy, Biomarkers, Tumor/metabolism ; Female ; Hormones ; Humans ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Progesterone/genetics ; Receptors, Progesterone/metabolism ; Registries

المؤلفون: Schmitz RSJM; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands., Geurts SME; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands., Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands., Tilli DJP; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands., de Boer M; Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.

المصدر: Cancers [Cancers (Basel)] 2021 Oct 20; Vol. 13 (21). Date of Electronic Publication: 2021 Oct 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Croes S; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tilli DJP; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Vriens IJH; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 571-581. Date of Electronic Publication: 2021 Mar 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/epidemiology, Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Netherlands/epidemiology ; Receptor, ErbB-2/genetics ; Registries ; Trastuzumab/therapeutic use

المؤلفون: Claessens AKM; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands; Department of Medical Oncology, Zuyderland Medical Center, PO BOX 5500, 6130 MB Sittard-Geleen, the Netherlands. Electronic address: anouk.claessens.91@gmail.com., Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: khava.ibragimova@mumc.nl., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: sandra.geurts@mumc.nl., Bos MEMM; Department of Medical Oncology, Erasmus Medical Centre, PO BOX 2030, 3000 CA Rotterdam, the Netherlands. Electronic address: m.bos@erasmusmc.nl., Erdkamp FLG; Department of Medical Oncology, Zuyderland Medical Center, PO BOX 5500, 6130 MB Sittard-Geleen, the Netherlands. Electronic address: f.erdkamp@zuyderland.nl., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

المصدر: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Sep; Vol. 153, pp. 102988. Date of Electronic Publication: 2020 May 26.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Capecitabine/therapeutic use ; Humans ; Quality of Life ; Taxoids/therapeutic use

المؤلفون: Schneider PP; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom., Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands., Passos VL; Department of Methodology and Statistics, CAPHRI Care and Public Health Research Institute Maastricht University, Maastricht, The Netherlands., Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Ibragimova KIE; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Erdkamp F; Zuyderland medical center, Sittard-Geleen, The Netherlands., Vriens BEPJ; Catharina hospital, Eindhoven, The Netherlands., van de Wouw AJ; VieCuri Medical Center, Venlo, The Netherlands., den Boer MO; Laurentius hospital Roermond, The Netherlands., Pepels MJ; Elkerliek Hospital, Helmond, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW - School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Joore MA; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, The Netherlands.

المصدر: PloS one [PLoS One] 2020 Apr 09; Vol. 15 (4), pp. e0230909. Date of Electronic Publication: 2020 Apr 09 (Print Publication: 2020).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms/*economics , Terminal Care/*economics, Aged ; Breast Neoplasms/mortality ; Breast Neoplasms/therapy ; Female ; Hospital Costs ; Hospitalization/economics ; Humans ; Linear Models ; Logistic Models ; Middle Aged ; Netherlands ; Palliative Care/economics ; Survival Rate

المؤلفون: Knapen LM; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; CAPHRI-Care and Public Health Research Institute, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: lotte.knapen@mumc.nl., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: sandra.geurts@mumc.nl., Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands. Electronic address: khava.ibragimova@mumc.nl., Croes S; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; CAPHRI-Care and Public Health Research Institute, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: s.croes@mumc.nl., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, PO BOX 1350, 5602 ZA Eindhoven, the Netherlands. Electronic address: birgit.vriens@catharinaziekenhuis.nl., van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center, PO BOX 5500, 6130 MB Sittard-Geleen, the Netherlands. Electronic address: f.vandenberkmortel@zuyderland.nl., Dercksen MW; Department of Internal Medicine, Máxima Medical Center, PO BOX 90052, 5600 PD Eindhoven, the Netherlands. Electronic address: m.dercksen@mmc.nl., van de Wouw AJ; Department of Internal Medicine, VieCuri Medical Center, PO BOX 1926, 5900 BX Venlo, the Netherlands. Electronic address: yvdwouw@viecuri.nl., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, PO BOX 98, 5700 AB Helmond, the Netherlands. Electronic address: mpepels@elkerliek.nl., de Fallois AOJ; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: aude.de.fallois@mumc.nl., Lobbezoo DJA; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: d.lobbezoo@mumc.nl., de Boer M; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: maaike.de.boer@mumc.nl., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, PO BOX 616, 6200 MD Maastricht, the Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

المصدر: Breast (Edinburgh, Scotland) [Breast] 2019 Apr; Vol. 44, pp. 46-51. Date of Electronic Publication: 2019 Jan 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

مواضيع طبية MeSH: Androstadienes/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Breast Neoplasms/*pathology , Everolimus/*therapeutic use, Aged ; Aromatase Inhibitors/therapeutic use ; Breast Neoplasms/metabolism ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Netherlands ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Treatment Outcome